Beta Bionics Announces Participation at Upcoming Investor Conferences
IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at upcoming investor conferences:
- Members of the Company’s management team will present at the Wolfe Research 8th Annual Healthcare Conference on Tuesday, November 10, 2026 at 12:40pm Eastern Time.
- Members of the Company’s management team will present at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 8:40am Eastern Time.
- Members of the Company’s management team will attend the Jefferies 2026 Global Healthcare Conference in London and host in-person meetings on Wednesday, November 18 and Thursday, November 19, 2026.
- Members of the Company’s management team will present at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026 at 12:00pm Eastern Time.
The presentations will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the events.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
Media gallery
